7,669.26

+37.79

+0.50%

53,083.67

+316.79

+0.60%

26,219.89

+120.11

+0.46%

2,956.57

+36.44

+1.25%

15.22

-1.12

-6.85%

4,431.00

+34.60

+0.79%

77,210.50

-66.66

-0.09%

Crude Oil Oct 26

91.00

+0.78

+0.86%

We are experiencing some temporary issues. The market data on this page is currently delayed.

Paris - Delayed Quote EUR

Transgene SA (TNG.PA)

Get top stock picks

0.7870 -0.0030 (-0.38%)

At close: 5:35:10 PM GMT+2

Get top stock picks

Chart Range Bar

AlphaSpace Chart

Loading chart for TNG.PA

Previous Close 0.7900
Open 0.7900
Bid --
Ask --
Day's Range 0.7840 - 0.7920
52 Week Range 0.7050 - 1.5000
Volume 39,654
Avg. Volume 50,764
Market Cap (intraday) 218.987M
Beta (5Y Monthly) 0.68
PE Ratio (TTM) --
EPS (TTM) -0.2600
Earnings Date --
Forward Dividend & Yield --
Ex-Dividend Date --
1y Target Est 1.10

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial. It has strategic collaboration agreements with NEC Corporation and NEC Bio, BioInvent, Merck & Co., Inc., Oxford Biomedica, Stamford, SillaJen, and ProBioGen. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

www.transgene.com

145

Full Time Employees

December 31

Fiscal Year Ends

Sector

Industry

Transgene and Nec Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications

Transgene and Nec Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications

Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress

Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress

Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026

Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026

Transgene Provides Business and Financial Update for Q1 2026

Transgene Provides Business and Financial Update for Q1 2026

Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028

Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028

Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer

Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer

Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine

Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine

Transgene SA (STU:TGNA) Full Year 2025 Earnings Call Highlights: Strategic Financial Moves and ...

Transgene SA (STU:TGNA) Full Year 2025 Earnings Call Highlights: Strategic Financial Moves and ...

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2026

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2026

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer

Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer

Transgene to Participate in Upcoming Investor Meetings

Transgene to Participate in Upcoming Investor Meetings

Trailing total returns as of 9/2/2026, which may include dividends or other distributions. Benchmark is CAC 40 (^FCHI) .

YTD Return

TNG.PA

18.02%

CAC 40 (^FCHI)

1.61%

1-Year Return

TNG.PA

28.78%

CAC 40 (^FCHI)

8.18%

3-Year Return

TNG.PA

55.23%

CAC 40 (^FCHI)

13.48%

5-Year Return

TNG.PA

72.29%

CAC 40 (^FCHI)

22.44%

Analyst Price Targets

1.10

1.10 Average

0.7870 Current

1.10 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Valuation Measures

  
  
 Annual 

As of 9/1/2026

Market Cap

219.82M
Enterprise Value

107.96M
Trailing P/E

--
Forward P/E

--
PEG Ratio (5yr expected)

--
Price/Sales (ttm)

233.02
Price/Book (mrq)

1.81
Enterprise Value/Revenue

220.34
Enterprise Value/EBITDA

--

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-24.21%
Return on Equity (ttm)

-54.80%
Revenue (ttm)

7.21M
Net Income Avi to Common (ttm)

-37.52M
Diluted EPS (ttm)

-0.2600

Balance Sheet and Cash Flow

Total Cash (mrq)

111.86M
Total Debt/Equity (mrq)

1.69%
Levered Free Cash Flow (ttm)

-25.12M

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

0.7870

-0.38%

Mkt Cap EUR 218.987M

Industry Biotechnology

0.0172

+3.61%

Mkt Cap EUR 253,486

Industry Biotechnology

Heidelberg Pharma AG

2.4200

-5.10%

Mkt Cap EUR 113.218M

Industry Biotechnology

Vivoryon Therapeutics N.V.

1.1300

-0.88%

Mkt Cap EUR 33.464M

Industry Biotechnology

1.0000

-0.79%

Mkt Cap EUR 13.635M

Industry Biotechnology

BioInvent International AB (publ)

24.50

+6.29%

Mkt Cap SEK 1.612B

Industry Biotechnology

Alligator Bioscience AB (publ)

0.0264

-3.30%

Mkt Cap SEK 24.41M

Industry Biotechnology

ABIONYX Pharma SA

1.9380

-1.42%

Mkt Cap EUR 82.024M

Industry Biotechnology

OSE Immunotherapeutics SA

3.2120

+0.50%

Mkt Cap EUR 77.512M

Industry Biotechnology

Innate Pharma S.A.

1.8000

+1.01%

Mkt Cap EUR 201.061M

Industry Biotechnology

Bio Green Med Solution, Inc.

2.8100

0.00%

Mkt Cap -

Industry Building Products & Equipment

IPH.PA Innate Pharma S.A.

1.8000 +1.01%

NANO.PA Nanobiotix S.A.

35.22 +5.13%

GNFT.PA Genfit S.A.

14.24 +0.85%

ALCLS.PA Cellectis S.A.

2.8420 -0.28%

AB.PA AB Science S.A.

0.7400 +0.54%

Mobilize your Website

View Site in Mobile | Classic

Share by: